Edgewise Therapeutics, Inc.
EWTX$1.20B
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaBOULDER136 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
3
Next Catalyst
Aug 6, 2026
6wMarket Overview
Stock performance and key metrics
EWTX News
Catalyst Timeline
4 upcoming, 1 past
Drug Pipeline
EDG-7500
Hypertrophic Cardiomyopathy
Sevasemten 10 mg
Becker Muscular Dystrophy
Sevasemten Dose 1
Duchenne Muscular Dystrophy
Sevasemten Dose 2
Duchenne Muscular Dystrophy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EDG-7500 | Phase 2 | Hypertrophic Cardiomyopathy | - | - |
Sevasemten 10 mg | Phase 2 | Becker Muscular Dystrophy | - | - |
Sevasemten Dose 1 | Phase 2 | Duchenne Muscular Dystrophy | - | - |
Sevasemten Dose 2 | Phase 2 | Duchenne Muscular Dystrophy | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply